4.8 Article

A BRISC-SHMT Complex Deubiquitinates IFNAR1 and Regulates Interferon Responses

Journal

CELL REPORTS
Volume 5, Issue 1, Pages 180-193

Publisher

CELL PRESS
DOI: 10.1016/j.celrep.2013.08.025

Keywords

-

Categories

Funding

  1. NIH/NCI [CA092900, CA142425, CA138835, CA17494, GM101149]
  2. Cancer Idea Award
  3. Harrington Discovery Institute Scholar-Innovator Award
  4. Pennsylvania Breast Cancer Coalition grant
  5. Abramson Family Cancer Research Institute
  6. Basser Research Center for BRCA

Ask authors/readers for more resources

Lysine63-linked ubiquitin (K63-Ub) chains represent a particular ubiquitin topology that mediates proteasome-independent signaling events. The deubiquitinating enzyme (DUB) BRCC36 segregates into distinct nuclear and cytoplasmic complexes that are specific for K63-Ub hydrolysis. RAP80 targets the five-member nuclear BRCC36 complex to K63-Ub chains at DNA double-strand breaks. The alternative four-member BRCC36 containing complex (BRISC) lacks a known targeting moiety. Here, we identify serine hydroxymethyltransferase (SHMT) as a previously unappreciated component that fulfills this function. SHMT directs BRISC activity at K63-Ub chains conjugated to the type 1 interferon (IFN) receptor chain 1 (IFNAR1). BRISC-SHMT2 complexes localize to and deubiquitinate actively engaged IFNAR1, thus limiting its K63-Ub-mediated internalization and lysosomal degradation. BRISC-deficient cells and mice exhibit attenuated responses to IFN and are protected from IFN-associated immunopathology. These studies reveal a mechanism of DUB regulation and suggest a therapeutic use of BRISC inhibitors for treating pathophysiological processes driven by elevated IFN responses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available